Arcus Biosciences, Inc.RCUSEarnings & Financial Report
NYSE · biotechnology industry
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 35.00% | 31.5M | flat | 2024-01-31 |
| BlackRock, Inc. | 10.60% | 9.7M | flat | 2024-11-08 |
| The Vanguard Group | 6.25% | 4.7M | — | 2024-02-13 |
| FMR LLC | 4.89% | 4.5M | ▼ -1.43pp | 2024-11-12 |
| Terry Rosen, Ph.D. | 4.10% | 3.8M | — | 2024-12-17 |
| STATE STREET CORPORATION | 3.30% | 3.0M | ▼ -2.36pp | 2024-10-17 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.